Cost of illness: A critical review of estimation methodologies
DOI:
https://doi.org/10.17533/udea.le.n77a12460Keywords:
Cost of Illness, Estimation MethodsAbstract
Studies on the cost of illness arise to advance knowledge and estimation of the economic burden of disease. These identify, quantify and value all the economic resources linked to a disease, and classify them as direct, indirect and intangible costs. The aim of this paper is to critically describe the different methods for estimating each of these costs. The valuation of the costs of an illness involves a vector of prices and quantities. The quantities arise from the resources used or lost. Prices are estimated from the market value of the good or service or, if it is a non-market good or service, then prices are estimated from proxy variables or specific methods of estimation of individual preferences. The main methodological and theoretical weaknesses found deal with the estimation of the ‘time’ resource, the presence of externalities and market imperfections and the violation of some assumptions of economic theory.
Downloads
References
Alonso, Jordi; Prieto, Luis & Antó, Josep (1995). “La versión española del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados clínicos”. Med Clin (Barc) Vol.104, pp.771-776.
Barfield, Jasse; Raiborn, Cecily & Kinney, Michel (2005). “Contabilidad de Costos Tradiciones e Innovaciones”. pp.77, 78 y 106, México.
Belotti, A.; Zeni, S.; Cossutta, R.; Soldi, A. & Fantini, F. (2003). “Analisi dei costi nella sclerosi sistemica. Studio retrospettivo in una casistica di 106 pazienti”. Reumatismo, Vol.55, pp.245–55.
Boardman, Anthony; Greenberg, David; Vining, Aidan & Weimer, David (1997). “Plug-in” shadow price estimates for policy analysis”. Ann Reg Sci, Vol.31, pp.299–324.
Brouwer, Roy (2000). “Environmental value transfer: state of the art and future prospects”. Ecological Economics, Vol. 32, pp. 137–152.
Brouwer, Warner; Van Exel, Job; Koopmanschap, Marc & Rutten, Frans (1999). “The valuation of informal care in economic appraisal. A consideration of individual choice and societal costs of time”. Int J Technol Assess Health Care, Vol.15, N°1, pp.147-60.
Canadian Coordinating Office For Health Technology Assessment (1997). Guidelines for economic evaluation of pharmaceuticals. Canada. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
Chan, Ben; Coyte, Peter & Heick, Caroline (1996). “Economic impact of cardiovascular disease in Canada”. Can J Cardiol, Vol.12, N°10, pp.1000-1006.
Chapko, Michael; Liu, Chuan-Fen; Perkins, Mark; Li, Yu-Fang; Fortney, John & Maciejewski Matthew (2009). “Equivalence of two healthcare costing methods: Bottom-up and top-down”. Health Econ, Vol.18, N°10, pp.1188-201.
Choi, Bo Kyoung & Pak Anita (2002). “A method for comparing and combining cost-of-illness studies: an example from cardiovascular disease”, Chronic Dis Can Spring, Vol. 23, N°2, pp.47-57.
Clabaugh, Gred & Ward, Marcia (2008). “Cost-of-Illness studies in the United States: a systematic review of methodologies used for direct cost”. Value Health, Vol.11, N°1, pp.13-21.
Common Wealth Of Australia (1995) Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmacuetical Benefits Advisory Committee: including economic analyses. Canberra, Departament of Health and Community Services.
Cusmano, Liliana; Morua, Sonia; Logran, Marcela; Pereyra, Ana & Palmero, Domingo (2009). “Estudio de los costos intangibles y de la participación del componente familiar en el costo social de la tuberculosis”. Revista Argentina de Salud Pública, Vol.1, No.1, pp.18-23.
Dagenais, Simon; Caro, Jaime & Haldeman, Scott (2008). “A systematic review of low back pain cost of illness studies in the United States and internationally”. Spine J, Vol.8, N°1, pp.8-20.
Drummond, Michael (1992). “Cost-of-illness studies: a major headache?”. PharmacoEconomics, Vol.2, N°1, pp.1–4.
Drummond, Michael; O’Brien, Bernard; Stoddart, Greg & Torrance, George (1987). Methods for the Economic Evaluation of Health Care Programmes. Oxford.
Evers, Silvia; Struijs, Jeroen; Ament, André; Van Genugten, Marianne; Jager, Jc & Van Den Bos, Geertrudis (2004) “International comparison of stroke cost studies”. Stroke, Vol. 35, pp.1209-1215.
Guyatt, Gordon; Feeny, David & Patrick, Donald (1993). “Measuring health-related quality of life”. Annals of Internal Medicine, Vol.118, pp.622-629.
Halvorsen, Peder & Kistiansen, Ivar (1996). “Radiology services for remote communities: cost minimisation study of telemedicine”. BMJ, Vol.312, No.7042, pp.1333–1336.
Hartunian, Nelson; Smart, Charles & Thompson, Mark (1980). “The Incidence and Economic Costs of Cancer, Motor Vehicle Injuries, Coronary Heart Disease, and Stroke: A Comparative Analysis”. Am J Public Health, Vol.70, No.12, pp.1249-60.
Hodgson, Thomas & Meiners, Mark (1982). “Cost of illness methodology: A guide to current practices and procedures”. Milbank Memorial Fund Quarterly, Vol.60, No.3, p.429-462.
Jeanrenaud, Claude & Priez, France (1999). Valuing intangible cost of lung cancer. 2nd World Conference of the International Health Economics Association, Rotterdam. Disponible en: 130.125.1.25/files/content/sites/ irene/files/shared/documents/wp00-01.doc
Johannesson, Magnus (1997). “Avoiding double-counting in pharmacoeconomic studies”. Pharmacoeconomics. Vol 11, No.5, pp.385-388.
Johannesson, Magnus & Karlsson, Göran (1997). “The friction cost method: a comment”. J Health Econ, Vol.16, pp.249-55.
Johannsson, Magnus; Meltzer, David & O´Conor, Richard (1997). “Incorporating Future Costs in Cost-Effectiveness Analysis: Implications for the Cost-Effectiveness of Hypertension Medical of the Treatment”. Med Decis Making, Vol. 17, pp.382-389.
Kleinbaum, David; Kupper, Lawrence & Morgenstern, Hal (1982). Epidemiologic research. Principles and quantitative methods. Canada.
Koopmanschap, Marc (1999). “Controversial costs in guidelines”. First Conference on Advances in Health Economics. Pompeu Fabra University. Barcelona.
Koopmanschap, Marc; Rutten, Frans; Van Ineveld, Martin & Van Roijen, Leona (1995). “The friction cost method for measuring indirect costs of disease”. Journal of Health Economics, Vol.14. pp.171-189.
Koopmanschap, Marc & Van Ineveld, Martin (1992). “Towards a new approach for estimating indirect costs of disease”. Social Science and Medicine, Vol.34, No.9, pp.1005-1010.
Liljas, Bengt (1998). “How to calculate indirect costs in economic evaluations”. Pharmacoeconomics, Vol.13, No.1 Pt 1, pp.1-7.
Liu, Jin-Lu; Maniadakis, Nikolaos; Gray, Andrew & Rayner, Mike (2002). “The Economic Burden of Coronary Heart Disease in the UK”. Heart, Vol.88, No.6, pp.597-603.
Lopez-Bastida, Julio; Serrando-Aguilar, Pedro & Duque-Gonzalez, Beatriz (2002). “Los costes socioeconómicos de las enfermedades cardiovasculares y del cáncer en las Islas Canarias en 1998”. Gac Sanit, Vol. 17, No.3, pp.210-217.
Luce, Bryan & Elixhauser, Anne (1990). “Estimating Costs in the Economic Evaluation of Medical Technologies”. Int J Technol Assess Health Care, Vol.6, No.1, pp.57-75.
Mata, Manuel; Antoñanzas, Fernando; Tafalla, Mónica & SANZ, Pilar (2002). “El coste de la diabetes tipo 2 en España”. Gaceta Sanitaria, Vol.16, No.6, pp.511 – 520.
Max, Wendy; Rice, Dorothy; Sung, Hai-Yen & Michel, Martha (2004). “Valuing Human Life: Estimating the Present Value of Lifetime Earnings, 2000”. UC San Francisco: Center for Tobacco Control Research and Education. Disponible en: http://escholarship.org/uc/item/82d0550k.
Oliva, Juan (2000). “La valoración de los costes indirectos en la evaluación sanitaria”. Med Clin (Barc) Vol.114, No.3, pp.15-21.
Oliva, Juan; Lobo, Felix; López-Bastida, Julio; Duque, Beatriz & Osuna, Rubén (2004). “Costes no sanitarios ocasionados por las enfermedades isquémicas del corazón en España”. Cuadernos Económicos ICE, Vol.67, pp.263-298.
Oliva, Juan; Lobo, Felix; Molina, Begoña & Monereo, Susana (2004). “Direct Healthcare Costs of Diabetes Mellitus Patients in Spain”. Diabetes Care, Vol.27, No.11, pp.2616-2621.
Oliva, Juan & Osuna, Rubén (2009). “Los costes de los cuidados informales en España”. Presupuesto y Gasto Público, Vol.56 pp.163-181.
Pato, Antonio; Cebrián, Ernesto; Cimas, Iciar; Lorenzo, José; Rodríguez, Iria & Gude, Francisco (2011). “Análisis de costes directos, indirectos e intangibles de la epilepsia”. Neurología. Vol.26, No.1, pp.32-38.
Pinto, José Luis & Puig-Junoy, Jaume (2001). “El coste de oportunidad del tiempo no remunerado en la producción de salud”. de Recerca en Economía i Salut Departtament d’ Economía i Empresa Universitat Pompeu Fabra, Vol. 1, No. 30, Madrid. Disponible en: http://www.econ.upf.edu/~puig/publicacions/paper40.pdf
Pinto-Prades, José Luis; Ortún-Rubio, Vicente & Puig-Junoy, Jaume (2001). “El análisis coste-efectividad en sanidad atención primaria”. Aten Primaria, Vol.27, No.4, pp.275-278.
Polimeni, Ralph; Fabozzi, Frank & Adelberg, Arthur (2003). Contabilidad de Costos. Conceptos y Aplicaciones para la toma de Decisiones Gerenciales. Bogotá.
Puig-Junoy, Jaume; Pinto-Prades, José Luis & Ortún-Rubio, Vicente (2001). “El análisis coste-beneficio en sanidad atención primaria”. Aten Primaria, Vol.27, No.6, pp.422-427.
Puig-Junoy, Jaume (2003). “La productividad de las innovaciones médicas y farmacéuticas”. Humanitas, Vol.1, No.3, pp.195-202.
Puig-Junoy, Jaume & Pinto, José Luis (2001). “El coste de oportunidad del tiempo remunerado en la producción de salud”. Centre de Recerca en Economía i Salut Departtament d’ Economía i Empresa Universitat Pompeu Fabra 2001, Vol. 1, No. 30. Disponible en: http://www.econ.upf.edu/~puig/publicacions/paper39.pdf
Rice, Dorothy (1969). “Measurement and application of illness costs”, Public Health Rep. Vol. 84, No. 2, pp.95–101.
Rice, Dorothy (1994). “Cost-of-illness Studies: Fact or fiction?”. Lancet, Vol.344, No. 8936, Dec 1994, pp.1519-20.
Rice, Dorothy (1967). “Estimating the cost of illness”. American Journal of Public Health, Vol. 57, N°3, pp.424-440.
Rice, Dorothy (2000). “Cost of illness studies: what is good about them?”. Injury Prevention, Vol.6, p.177–179.
Rice, Dorothy & Cooper, Barbara (1967). “The economic value of human life”. Amer J Public Health, Vol. 57, No.11, pp.1954–1966.
Rice, Dorothy & Hodgson, Thomas (1982). “The value of human life revisited”. American Journal of Public Health, Vol.72, No.6, pp.536-538.
Rice, Dorothy; Hodgson, Thomas & Kopstein, Andrea (1985), “The economic cost of illness: a replication and update”. Health Care Financ Rev, Vol.7, No.1, pp.61-80.
Rivera, Berta; Casal, Bruno & Currais, Luis (2008). “Estudio económico del tiempo de cuidado informal como factor de producción de salud en el enfermo de Alzheimer no institucionalizado”. Madrid: Fundación de Estudios de Economía Aplicada. Colección Estudios Económicos 16-08. Serie Economía de la Salud y Hábitos de Vida. Disponible en: http://www.fedea.es/pub/est_economicos/2008/16-08.pdf
Segel, Joel (2006). Cost-of-Illness Studies - A Primer. Research Triangle Park: RTI-UNC Center of Excellence in Health Promotion Economics.
Szucs, Thomas; Berger, Karin; Fisman, David & Harbarth, Stephan (2001). “The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches”. BMC Infect Dis, pp.1:5.
Tárraga, Pedro; Celada, Ángel; Cerdán, Miguel; Albero, Juan; Ocaña, José & Clavé, Jaime (2001). “Análisis coste-efectividad de atorvastatina frente a simvastatina como tratamiento hipolipemiante en pacientes hipercolesterolémicos en atención primaria”, Aten Primaria, Vol.27, pp.18- 24.
Tarricone, Rossana (2006). “Cost-of-illness analysis. What room in health economics?”. Health Policy, Vol.77, No.1, pp.51-63.
Van Den Berg, Bernard; Brouwer, Werner & Koopmanschap, Marc (2004). “Economic valuation of informal care. An overview of methods and applications”. Eur J Health Econ, Vol.5, No.1, pp.36-45.
Van Roijen, Leona; Koopmanschap, Marc; Rutten, Frans & Van Der Maas, Paul (1995).“Indirect costs of disease; an international comparison”. Health Policy, Vol.33, No.1, pp.15-29.
Viteri, César; Codina, Montserrat; Cobaleda, S.; Lahuerta, Juan; Barriga, J.; Barrera, S. & Morales, Martha (2008). “Validación de la versión española del cuestionario de calidad de vida en epilepsia QOLIE-10”. Neurología, Vol.23, No.3, pp.157-167.
Wimo Anders (2010). “The Art of Cost of Illness”. J Alzheimers Dis.,Vol.19, No.2, pp.617-9.
World Health Organization (WHO) (2011). Global status report on noncommunicable diseases 2010, World Health Organization 2011.
Published
How to Cite
Issue
Section
License
This page, by Universidad de Antioquia, is licensed under a Creative Commons Attribution License.
Authors who publish with this journal agree to retain copyright and grant the journal right of first publication, with the article licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License allowing others to share it as long as they acknowledge its authorship and original publication in this journal.
Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), provided that these arrangements be not for profit and the journal be acknowledged as the original source of publication.
Authors are permitted and encouraged to post their papers online (e.g., in institutional repositories or on their websites), as it can lead to valuable exchanges as well as greater citation of the published work.
